ISAD × WHO day

Introduction

Purpose and General Structure of the Day 1.

Dear Colleagues,

We are pleased to welcome you to the ISAD × WHO Day on Friday, 16 October 2026, immediately before the Rajka Symposium in Beijing. The meeting will bring together clinicians, researchers, methodologists, patient representatives, global-health partners, and other stakeholders to advance two closely linked priorities in atopic dermatitis: an international Treat-to-Target consensus and equitable access to effective care.

The meeting builds on the Treat-to-Target initiative launched during the ISAD × WHO pre-meeting in Melbourne in October 2025 (the publication is available here). Since then, ISAD, the International Eczema Council (IEC), and the Global Atopic Dermatitis Atlas (GADA) have established a shared pathway toward a patient-centered and methodologically rigorous consensus on meaningful long-term disease control, with methodological coordination from the Charité Berlin team.

The invitation-only morning workshop will focus on evidence mapping, patient-reported outcomes, data-informed candidate targets, global feasibility, and the future Delphi and consensus process. The afternoon session, which will include industry partners, will discuss ISAD × WHO projects, access to care, and essential medicines in the context of regional implementation challenges and patient priorities.

We look forward to your active participation throughout the day and to a focused discussion that will translate shared principles into practical next steps.

Alain TAÏEB
President, International Society of Atopic Dermatitis
On behalf of ISAD

Venue 2.

CCI France Chine Beijing Office
No. 4 Gongti North Road, Chaoyang District, Beijing 100027, P.R. China

ACCESS: Tianjiehu Metro Station (exit D), Line 10 - 3 minutes walking distance.
The entrance of the CCIFC is located in the corner of the building 81, the office is on the 2nd floor of Building 81.

+86 (010) 6461 0260 | ccifc-beijing@ccifc.org | GMAPS | WEBSITE | METRO MAP

Program of the Day

Please note all timings are based on Beijing time zone.
➜ China Standard Time (CST) – UTC+08:00

	Morning Session ~Closed to the Industry
07:30	Meeting in the Lobby of the China World Hotel + Shuttle Bus to the venue (CCIFC)
08:30 12:30	Treat-to-Target in Atopic Dermatitis: From Concept to Data-Informed Consensus Methodology Chairs: Alan IRVINE, Carsten FLOHR & Tina MESARIC Rapporteurs: Fang WANG, Andreas WOLLENBERG & John SU
08:30 09:00	Arrival and registration for closed workshop ISAD / local organizing team
09:00 09:10	Welcome and objectives of the ISAD × WHO day Alain TAÏEB, Lin MA, John SU
09:10 09:30	T2T consensus in atopic dermatitis: from the Melbourne kickoff to Beijing Alain TAÏEB
09:30 10:00	Patient-reported outcomes, patient-centered medicine, pediatric aspects, and meaningful disease control Kathy GIBSON (Rheumatologist), Li-Chuen WONG (Pediatric dermatologist), Vildana MUJKIC (patient representatives)
10:00 10:30	Coffee break
10:30 10:50	From evidence mapping to data-driven T2T targets: proposed analytical framework Ruben HEUER (Charité Berlin methodology team)
10:50 11:20	Roundtable: Integrating evidence mapping, longitudinal RCT analyses, and the ISAD T2T position paper into the consensus process All
11:20 11:50	Global feasibility: adapting targets across high-, middle- and low-resource settings African and Asian guideline task force representatives Sandipan DHAR & Erereoghor OTROFANOWEI
11:50 12:30	Roundtable: Next steps in preparation for the T2T consensus meeting at the 2027 Rajka Symposium in Augsburg All
12:30–13:30	Lunch
	Afternoon Session ~Open to the Industry
13:30 18:00	ISAD–WHO projects, access to care, and the 2027 WHO Essential Medicines List perspective Chairs: Peter SCHMID-GRENDELMEIER, Lawrence EICHENFIELD & Lorenzo MOJA Rapporteurs: Michele RAMIEN & Magdalena TRZECIAK
13:30 13:40	Welcome to the afternoon session with industry participation Chairs
13:40 14:20	Essential medicines and atopic dermatitis: balancing innovation, access and public health priorities Lorenzo MOJA
14:20 14:40	ILDS-led project for the 2027 EML cycle: methotrexate and dupilumab Carsten FLOHR
14:40 15:10	Follow-up to the inclusion of urea- and glycerol-based emollients on the WHO EML Core List Marie LODÉN
15:10 15:30	Coffee break
15:30 16:15	Integrated moderated discussion: access to topical and systemic treatments; regional implementation perspectives; patient priorities and communication; evidence generation, affordability, and responsible access Regional representatives; patient and advocacy representatives; industry contributors; all participants
16:15 16:25	Reports from the morning T2T workshop and afternoon session: key conclusions and agreed action points Morning and afternoon rapporteurs
16:25 16:30	Closing remarks and next steps for the ISAD Beijing 2026 main Symposium Alain TAÏEB, Lin MA, John SU
07:30	Shuttle Bus to the China World Hotel Non Board Member Participants can refresh and rest
16:30 19:30	Afternoon break
17:00 19:00	ISAD General Assembly For the ISAD Board Members only
19:00	Mini Bus to the Temple Board Members only
	Evening Session ~Open to All Registered Attendees of the WHO Day
19:00	Meeting in the Lobby of the China World Hotel + Shuttle Bus to the SongZhu Temple All participants
20:00 22:30	Venue: SongZhu Temple Complex, Dongcheng District, Beijing No. 23 Shatan North Street, Dongcheng District, Beijing, China +86 139 1171 2083 Participants are cordially invited to a informal welcome reception and networking evening. Located in Beijing’s historic Hutong district, the venue offers a quiet setting for dialogue and international exchange following the day’s scientific program.
22:30	Shuttle Bus back to the China World Hotel All participants

Invited Participants by Region of Origin

ALL 61 IN-PERSON 61 REMOTELY EXCUSED

Participant		Country Area	Affiliation	Role / Reason for invitation
WHO / Global Access
Lorenzo	MOJA	Switzerland	WHO Int. EML	2027 EML discussion / WHO interface
Yukun	FANG	China	WHO China	WHO China
Europe
Alain	TAÏEB	France	ISAD	ISAD chair; afternoon and main-meeting report
Peter	SCHMID-GRENDELMEIER	Switzerland	ISAD	ISAD / allergy-dermatology interface
Ruben	HEUER	Germany	Charité
Andreas	WOLLENBERG	Germany	ISAD	Morning workshop rapporteur; T2T steering
Dirk-Jan	HIJNEN	The Netherlands	ISAD	AD expert / T2T discussion
Magdalena	TRZECIAK	Poland	ISAD	AD expert / European perspective
Mikael	ALSTERHOLM	Sweden	TSW group	TCS concern / TSW interface
Carsten	FLOHR	United Kingdom	GADA	GADA / ILDS leadership for EML project
Marie	LODÉN	Sweden	Pharmacist and dermatologist	EML consultant / emollient access discussion
Asia-Pacific
Eung	CHOI	South Korea	IEC	Korean / Asian perspective
Sandipan	DHAR	India	ISAD, IEC, GADA Steering Committee	Asian AD guidelines task force
Maria Victoria	DIZON	Philippines		APADtf
Kathryn	GIBSON	Australia	Rheumatology PROMs	Patient-reported outcomes / measurement
Somesh	GUPTA	India		Indian perspective
Smita	JOSHI	Nepal	APADtf	Nepal / South Asian perspective
Ajith	KANNANGARA	Sri Lanka	APADtf	Sri Lankan perspective
Kyu Han	KIM	South Korea	ISAD, IEC	Korean / Asian AD perspective
JiHyun	LEE	South Korea	APADtf	Korean perspective
Dong Hun	LEE	South Korea	IEC	Korean AD perspective
Wei	LI	China	Dermatology	Chinese host-country perspective
Ashoka	LIYANAGE	Sri Lanka	Skin Sri Lanka	Australian / Asia-Pacific perspective
Lin	MA	China	ISAD, IEC	Co-Chair, Chinese host / pediatric dermatology
Wilsie	SALAS-WALINSUNDIN	Philippines	APADtf	Philippine perspective
John	SU	Australia	ISAD	Morning workshop rapporteur; pediatric AD
Fang	WANG	China	Dermatology	Chinese host-country perspective
Hua	WANG	China	GADA collaborator	Chinese host-country perspective
Li-Chuen	WONG	Australia	APADtf	Australian / Asia-Pacific perspective ; pediatric AD
Anousha	YAZDABADI	Australia	Dermatology	Australian / Asia-Pacific perspective
Jianzhong	ZHANG	China	Dermatology	Chinese perspective
Africa
Boubacar	AHY DIATTA	Senegal	ASDV	African perspective
Antoinette	CHATEAU	South Africa	ASDV	African perspective
Olufolakemi	COLE	Nigeria	ASDV	African perspective
Mahira	EL-SAYED	Egypt	ASDV	African perspective
Suretha	KANNENBERG	South Africa	ASDV	African perspective
Kayitesi	KAYITENKORE	Rwanda	ASDV	African perspective
Emmanuel	KOUOTOU	Cameroon	ASDV	African perspective
Gloria	MASENGA	RDTC / Tanzania	ISAD-GADA Fellow	African training / capacity building
Shimelis	NIGUSSE DONI	Ethiopia	ASDV	African perspective
Erereoghor	OTROFANOWEI	Nigeria	ISAD, ASDV, GADA Collaborator	African AD guidelines task force
Amina	OUEDRAOGO	Burkina Faso	ASDV	African perspective
Fahafahantsoa	RAPELANORO RABENJA	Madagascar	ISAD, GADA Steering Committee, ASDV	African perspective
Fandresena	SENDRASOA	Madagascar	ASDV	African perspective
North America
Michele	RAMIEN	Canada	ISAD, IEC	Pediatric AD
Lawrence	EICHENFIELD	USA	IEC	IEC leadership
Peter	LIO	USA	IEC, ITSAN interface	TCS concern / TSW
Eric	SIMPSON	USA	IEC, ISAD	AD outcomes
South/Latin America
Roberto	TAKAOKA	Brazil	ISAD Vice-President	Patient-centered medicine
Javier	ARELLANO LORCA	Chile	ISAD	Latin American perspective
Industry representatives (afternoon only)
Arti	BAIG	United States of America	LEO Pharma
João	COSTA	Portugal	Sanofi
Marketa	SAINT AROMAN	France	Pierre Fabre
Salwa	TUNIO	Denmark	LEO Pharma
Nicole	WALSH	United States of America	Abbvie
Wenyan	ZHANG	China	Abbvie

Patient and Advocacy Participation 3.

Seven patient representatives or advocacy participants are currently planned:

Participant		Country / area	Perspective
Jennifer	AUSTIN	Canada	GlobalSkin
Kristin	BELLESON	USA	National Eczema Association
Melanie	FUNK	Australia	Patient representative
Brandon	HU	Australia	Patient / clinician advocate
Ursula	SOH	Singapore	Patient advocate

Their contribution will be central to both the morning Treat-to-Target session and the afternoon discussion on access, communication, safety concerns, and meaningful disease control.

Roles of ISAD, IEC, GADA, WHO, ILDS, and Industry 4.

ISAD

ISAD will convene the meeting and coordinate the overall scientific agenda. ISAD will lead the Treat-to-Target consensus project, patient-centered discussions, regional guideline links, and reporting to the main Rajka meeting.

IEC

IEC will be involved throughout the day, especially in the Treat-to-Target consensus development and in ensuring alignment with international AD expertise.

GADA

GADA will contribute to global epidemiology, disease burden, metrics, and implementation perspectives of the T2T project. Through Carsten Flohr, GADA will also provide the operational link with ILDS for the access-to-medicines project.

WHO

WHO via Lorenzo Moja will contribute to the discussion on essential medicines and access to care, particularly in relation to the 2027 WHO Essential Medicines List process.

ILDS

ILDS, via Carsten Flohr/GADA, will be in command of the main project for possible inclusion of methotrexate and dupilumab in the 2027 WHO Essential Medicines List cycle (expected submission in September 2027).

Industry

Industry participants will be invited separately for the afternoon session. They will not participate in the closed morning workshop. In the afternoon, they will not be limited to observer status and may contribute actively during moderated discussions.